Hormones and bone health in postmenopausal women |
| |
Authors: | Lindsay Robert |
| |
Institution: | (1) Helen Hayes Hospital, West Haverstraw, NY, and Department of Medicine, Columbia University, New York, NY |
| |
Abstract: | Although it has been known for some time that estrogen deficiency is a major pathogenetic factor for osteoporosis related
fractures among postmenopausal women, the capability of estrogen (with or without a progestin) to prevent fractures has often
been questioned. The publication of the data from the two hormone clinical trials of the Women’s Health Initiative lays that
discussion to rest. In both studies what have been considered a standard dose of conjugated estrogen with or without medroxyprogesterone
acetate significantly reduced the risk of all fractures, including clinical vertebral fractures and hip fracture, in a population
of postmenopausal women, average age 63 yr, not selected for osteoporosis by BMD. These results are particularly impressive
given the difficulty of finding a fracture benefit in lower risk populations with other anti-resorptive agents. Surrogate
data on lower doses of hormone therapy suggest a fracture benefit would be seen if studies were to be done. The other outcomes
in WHI make it important to define appropriate clinical guidelines for use of hormone therapy for prevention of fractures
in postmenopausal women. |
| |
Keywords: | Osteoporosis estrogen WHI fractures |
本文献已被 PubMed SpringerLink 等数据库收录! |
|